[1] McDermott JD, Bowles DW. Epidemiology of head and neck squamous cell carcinomas: impact on staging and prevention strategies [J]. Curr Treat Options Oncol, 2019, 20(5): 43. [2] Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: diferences by country, sex and anatomic site [J]. Oral Oncol, 2014, 50(5): 387-403. [3] Kitamura N, Sento S, Yoshizawa Y, et al. Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma [J]. Int J Mol Ssi, 2020, 22(1): 240. [4] Hoischen C, Yavas S, Wohland T, et al. CENP-C/H/I/K/M/T/W/N/L and hMis12 but not CENP-S/X participate in complex formation in the nucleoplasm of living human interphase cells outside centromeres [J]. PLoS One, 2018, 13 (3): e0192572. [5] Talbert P, Henikoff S. Centromere drive: chromatin conflict in meiosis [J]. Curr Opin Genet Dev, 2022, 77: 102005. [6] Zheng Y, You H, Duan JZ, et al. Centromere protein N promotes lung adenocarcinoma progression by activating PI3K/AKT signaling pathway [J]. Genes Genomics, 2022, 44(9): 1039-1049. [7] Andres SA, Bickett KE, Alatoum MA, et al. Interaction between smoking history and gene expression levels impacts survival of breast cancer patients [J]. Breast Cancer Res Treat, 2015, 152 (3): 545-556. [8] Wu HL, Zhou Y, Wu HY, et al. CENPN acts as a novel biomarker that correlates with the malignant phenotypes of glioma cells [J]. Front Genet, 2021, 12: 732376. [9] Wang QQ, Yu XY, Zheng ZW, et al. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma [J]. PeerJ, 2021, 9: e11342. [10] Rahman MR, Islam T, Gov E, et al. Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: insights from systems biology analysis [J]. Medicina, 2019, 55 (1): 20. [11] Oka N, Kasamatsu A, Endo-Sakamoto Y, et al. Centromere protein N participates in cellular proliferation of human oral cancer by cell-cycle enhancement [J]. J Cancer, 2019, 10(16): 3728 -3734. [12] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J]. Int J Cancer, 2019, 144(8): 1941-1953. [13] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma [J]. Nat Rev Dis Primers, 2020, 6(1): 92-92. [14] Zhou K, Gebala M, Woods D, et al. CENP-N promotes the compaction of centromeric chromatin [J]. Nat Struct Mol Biol, 2022, 29(4): 403-413. [15] Qi CL, Huang ML, Zou Y, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis [J]. J Exp Clin Cancer Res, 2021, 40(1): 390. [16] Zhang HY, Zhang W, Sun LL, et al. HJURP inhibits proliferation of ovarian cancer cells by regulating CENP-A/CENP-N [J]. Bull Cancer, 2022, 109(10): 1007-1016. [17] Navarro AP, Cheeseman LM. Dynamic cell cycle-dependent phosphorylation modulates CENP-L-CENP-N centromere recruitment [J]. Mol Biol Cell, 2022, 33(10): ar87. [18] Jonathan IE, Mahul BA, Samson WF, et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer [J]. Arch Pathol Lab Med, 2021, 145(4): 461-493. [19] Lawrence JO, Rebecca A, Michael V, et al. Effect of age and gender in non-smokers with oral squamous cell carcinoma: Multi-institutional study [J]. Oral Oncol, 2021, 116: 105210. [20] Anne KHA, Elisabeth B, Hans JA. Personality, choice of coping and T stage predict level of distress in head and neck cancer patients during follow-up [J]. Eur Arch Otorhinolaryngol, 2012, 269(9): 2121-2128. [21] Guigay J, Auperin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial [J]. Lancet Oncol, 2021, 22(4): 463-475. [22] Okada M, Kato K, Cho BC, et al. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3) [J]. Clin Cancer Res, 2022, 28(15): 3277-3286. |